Combined and Separate Effects of Cannabis and Tobacco: Psychomotor, Subjective and Physiological Outcomes
NCT05526196
Recruiting
Co-administration of cannabis and tobacco is a common practice, but there is little experimental evidence aimed at understanding the reasons for this prevalence. Some preliminary evidence suggests that tobacco may actually counteract the cognitive-impairing effects of cannabis, and may also increase the subjective ('liking') effects of cannabis, but results are inconclusive. Further, there are no studies into the effects of tobacco on other cannabis-related harms such as driving, or on the abili... Read More
Gender:
ALL
Ages:
Between 19 years and 45 years
Trial Updated:
02/21/2025
Locations: Centre for Addiction and Mental Health, Toronto, Ontario
Conditions: Driving Under the Influence
Register for Updates
Appetitive Conditioning in Anorexia Nervosa
NCT05531604
Recruiting
Anorexia nervosa (AN) is characterized by a reduced drive to pursue rewarding experiences and stimuli. Food consumption - which is almost universally experienced as pleasurable - is not described as rewarding by those with AN. This is thought to be underpinned by abnormalities around reward learning. However, the most fundamental question relating to reward in AN - whether those with AN may learn positive associations - remains unaddressed. In this study, the investigators will identify the pat... Read More
Gender:
FEMALE
Ages:
Between 12 years and 22 years
Trial Updated:
02/21/2025
Locations: Centre for Addiction and Mental Health, Toronto, Ontario
Conditions: Anorexia Nervosa
Register for Updates
TMS Visual Modulation in Body Dysmorphic Disorder
NCT05607121
Recruiting
The goal of this observational study is to test the effects of a type of noninvasive brain stimulation called transcranial magnetic stimulation (TMS) on visual processing in adults with body dysmorphic disorder symptoms when combined with modifying visual attention. The main goals are to understand, in people with body dysmorphic disorder and people with subclinical body dysmorphic disorder: * The effects of intermittent and continuous TMS stimulation of parietal brain regions when done right... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
02/21/2025
Locations: Centre for Addiction and Mental Health, Toronto, Ontario
Conditions: Body Dysmorphic Disorders
Register for Updates
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
NCT05958407
Recruiting
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: LEO Pharma Investigational Site, Birmingham, Alabama +75 locations
Conditions: Atopic Dermatitis, Atopic Hand Eczema
Register for Updates
Early-life MRI Biomarkers of Longer-term Respiratory Morbidity in Infants Born Extremely Preterm (EMBLEM)
NCT06065215
Recruiting
Bronchopulmonary dysplasia (BPD) is a common, major complication of premature birth, associated with developmental and health consequences that continue into adulthood. Prediction of who will have these problems is challenging using traditional definitions of disease. It is believed that underdevelopment and injury occur in both lung tissue and the blood vessels in the lungs, with a sophisticated interplay between them that contributes to lung disease seen in prematurity. New magnetic resonance... Read More
Gender:
ALL
Ages:
Between 35 weeks and 21 months
Trial Updated:
02/21/2025
Locations: The Children's Hospital of Eastern Ontario, Ottawa, Ontario +3 locations
Conditions: Lung Function, BPD - Bronchopulmonary Dysplasia
Register for Updates
Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD
NCT06299319
Recruiting
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. There is interest to see if similar effects may be provided in those with obsessive compulsive disorder (OCD). The purpose of this study is to evaluate the safety, feasibility, and clinical effects of psilocybin administration in those with OCD. Ten participants with treatment-resistant OCD will receive... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/21/2025
Locations: Centre for Addiction and Mental Health, Toronto, Ontario
Conditions: Obsessive-Compulsive Disorder
Register for Updates
Psilocybin for Treatment-Resistant Depression in Autism with Pre-Post Brain and Cognitive Measurement to Understand Mechanisms
NCT06731621
Recruiting
We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD). In this study, 20 participants (intellectually able and fluent-speech adults) with autism and co-occurring TRD will receive around 20 hours of manualized psychotherapy that has previously been used with psilocybin (Agin-Liebes et al., 2020). They will also receive psilocybin at 2 different time... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/21/2025
Locations: Centre for Addiction and Mental Health, Toronto, Ontario
Conditions: Treatment Resistant Depression, Autism Spectrum Disorder
Register for Updates
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
NCT05356195
Recruiting
This is a single-dose, open-label study in pediatric participants with TDT. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
02/20/2025
Locations: SCRI at the Children's Hospital at TriStar Centennial, Nashville, Tennessee +5 locations
Conditions: Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
Register for Updates
Therapeutic Effects of Electrical Vestibular Stimulation (EVS) on Balance and Gait
NCT06846047
Recruiting
The aim of the study to is determine the safety, feasibility, efficacy, and persistence of non-invasive EVS to improve balance and gait performance in healthy individuals across the lifespan. Specifically, our objective is to measure balance and gait performance before, during and after exposure to single sessions and across repeated sequences of EVS at multiple study partner sites.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/20/2025
Locations: Caring Hands Caregivers, Cupertino, California +3 locations
Conditions: Vestibulopathy
Register for Updates
Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial
NCT06093126
Recruiting
Insomnia is a highly common, chronic disorder that is distressful for the patient but also for caregivers and can give rise to a heavy burden on the healthcare team. Sleeping aids like benzodiazepines and other sedatives (e.g., zolpidem, zopiclone) have been widely used to help treat insomnia. However, sleeping aids are also known to cause adverse drug reactions such as drowsiness and dizziness, that increases the risk of falls, driving impairment, visual impairment, cognitive impairment, and up... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/20/2025
Locations: Nova Scotia Health, Halifax, Nova Scotia
Conditions: Insomnia, Dementia, Frontotemporal Dementia
Register for Updates
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
NCT06257706
Recruiting
Transmural healing (TMH) is recognized as a potentially important measure of Crohn's disease (CD) activity but not a formal target. Observational studies suggest that TMH may be associated with better long-term outcomes. The study will evaluate TMH using noninvasive intestinal ultrasound (IUS), a patient-friendly technique that can be performed routinely in clinical practice. The aim of the study is to determine if treating to a target of corticosteroid-free (CS-free) IUS outcomes + clinical sym... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/20/2025
Locations: TLC Clinical Research Inc - Los Angeles, Los Angeles, California +72 locations
Conditions: Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
Register for Updates
Pelvic Floor Muscle Training for Women with Myotonic Dystrophy
NCT06316778
Recruiting
Myotonic dystrophy type 1 (DM1) is a neuromuscular disease characterized by multisystem manifestations. DM1 can affect the urinary system through the impact of the pelvic floor muscles (PFM). Urinary incontinence can occur in this situation and is often offset with compensatory measures without restoring the PFM function (e.g. sanitary pads). PFM training have already been shown to be effective in reducing or even eliminating urinary incontinence in the general population. However, no study has... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Clinique des maladies neuromusculaires, Jonquière, Quebec
Conditions: Myotonic Dystrophy Type 1, Urinary Incontinence
Register for Updates